FIELD: medicine.
SUBSTANCE: invention concerns medicine and pharmacy area, in particular, to the medical products used for treatment of epilepsy and neuropathic pain. The agent contains carbamazepine and thyotriazoline in a mass parity 1: (0.25-2.5) in quality of an active base according to the invention. The agent possesses anticonvulsant, neuroprotective, nootropic, analgetic, antidepressive, actoprotective and antioxidatic action. Use of the combined agent under the invention allows to raise efficiency of treatment of the specified diseases in comparison with use of carbamazepine and thyotriazoline separately and to lower implication of toxic action of an agent at treatment.
EFFECT: rising of efficiency of treatment of the specified diseases in comparison with use of carbamazepine and thyotriazoline separately and depression of implication of toxic action of an agent at treatment.
9 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING PAROXYSMAL CONDITIONS | 2011 |
|
RU2469722C1 |
| 4-BENZOYLPYRIDINE OXIME DERIVATIVES HAVING ANTICONVULSANT ACTIVITY AS AGENTS FOR TREATMENT OF EPILEPSY AND PAROXYSMAL STATES | 2016 |
|
RU2643091C2 |
| CEREBRAL PROTECTIVE AND STRESS-PROTECTIVE MEDICINAL AGENT "NOOTRIL" AS INJECTION SOLUTION | 2003 |
|
RU2268711C2 |
| COMBINED ANTIAGGREGANT AND ANTIOXIDANT | 2010 |
|
RU2430728C1 |
| 4-(3,4-DIBROMOTHIOPHENE CARBONYL)-2,6,8,12-TETRAACETYL-2,4,6,8,10,12-HEXAAZATETRACYCLO[5,5,0,0,0]DODECANE USED AS AN ANTICONVULSANT | 2018 |
|
RU2684107C1 |
| COUMARIN, THIOCOUMARIN AND QUINOLINONE DERIVATIVES, HAVING ANTICONVULSANT ACTIVITY | 2017 |
|
RU2720510C2 |
| METHOD OF REDUCING PRO-OXIDANT ACTION OF ANTICONVULSANTS IN EXPERIMENT | 2019 |
|
RU2715679C1 |
| COMBINED DRUG OF ANXIOLITHIC, STRESS-PROTECTOR, NOOTROPIC AND ANTIOXIDANT ACTION | 2016 |
|
RU2625754C1 |
| THERAPEUTIC PREPARATION AT SPASMODIC SYNDROME | 2001 |
|
RU2191017C1 |
| AGENT HAVING ANTICONVULSANT ACTIVITY | 2024 |
|
RU2828199C1 |
